n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, January 19th, 2018

The QualityStocks
Daily Stock List

graphic
graphic

Rezolute, Inc. (RZLT)

OTC Markets, MarketWatch, Morningstar, InvestorsHub, 4-Traders, Barchart, Stockhouse, Street Insider, The Street, Stockopedia, Dividend Investor, Simply Wall St, and YCharts reported on Rezolute, Inc. (RZLT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Based in Louisville, Colorado, Rezolute, Inc. is a clinical stage biopharmaceutical company. It specializes in the development of unique drug therapies for metabolic and orphan diseases. The Company previously went by the name AntriaBio, Inc. It changed its name to Rezolute, Inc. in December of 2017. Rezolute’s shares trade on the OTC Markets Group’s OTCQB.

The Company is advancing a varied pipeline. This pipeline includes RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy. The pipeline also includes AB101 (Phase 1). This is a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management through lessening the therapeutic burden for patients and improving compliance.

Rezolute’s pipeline also includes a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 targeting Diabetic Macular Edema (DME) and RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.

In early December 2017, Rezolute and XOMA Corporation announced that they executed a license agreement. This agreement provides Rezolute with the exclusive worldwide rights to develop and commercialize RZ358 (previously XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication. XOMA is a pioneer in the discovery, development, and licensing of therapeutic antibodies.

RZ358 is a first-in-class fully human monoclonal antibody. It counteracts the effects of elevated insulin by way of allosteric modulation of the insulin receptor. This makes it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI.

Recently, Rezolute announced that it entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC). LPC is a Chicago-based institutional investor. LPC manages a portfolio of investments in public and private entities.

After the Securities and Exchange Commission (SEC) declares an effective registration statement regarding the transaction, Rezolute will have the right and sole discretion to sell up to $10 million worth of shares to LPC over a 36-month period, subject to certain limitations.

Rezolute will control the timing and amount of any future investment. LPC will be obligated to make purchases in accordance with the Agreement. Proceeds from the Agreement will be used for operations. They will also be used to advance the development of Rezolute’s product candidates and product collaborations.

Rezolute, Inc. (RZLT), closed Friday's trading session at $0.90, even for the day, on 3,125 volume with 7 trades. The average volume for the last 60 days is 3,689 and the stock's 52-week low/high is $0.65/$0.99.

eWellness Healthcare Corp. (EWLL)

StockHideout and Penny Stock Prodigy reported previously on eWellness Healthcare Corp. (EWLL), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, eWellness Healthcare Corp. develops a telemedicine platform. This platform is for providing Distance Monitored Physical Therapy programs. These programs are for pre-diabetic, cardiac, and health challenged patients through contracted physician practices and healthcare systems. eWellness Healthcare is headquartered in Culver City, California.

The Company has launched PHZIO. The design of this Physical Therapy Telemedicine platform is to extend and scale a physician’s practice. eWellness Healthcare is the first physical therapy telemedicine company to provide insurance reimbursable real-time distance monitored treatments.

eWellness Healthcare’s business model is to license the PHZIO platform to any Physical Therapy (PT) clinic in the U.S. and/or have large-scale employers use its PHZIO platform as a completely PT monitored corporate wellness program. eWellness Healthcare’s PHZIO extends a traditional practice online.

The main features of the PHZIO platform include video treatment protocols, real-time patient monitoring, patient induction forms, a patient video journal, and post treatment evaluations. Furthermore, main features include integrated billing, patient metrics, as well as user administration & customization.

PHZIO also scales a practice’s billable rates. In addition, it provides tools to make growing a business easier.

Regarding the Patient Dashboard, the PHZIO Dashboard enables clients to login securely to access prescribed treatment protocols. PHZIO is user-friendly and highly reliable to operate for PT and Patient. It is also a complete on-line PT telemedicine intervention system.

Evolution Physical Therapy has added eWellness Healthcare's Telehealth PT Services at its four clinical locations in Los Angeles, California. This includes Culver City, Playa Vista, Beverly Hills, and Brentwood. Mr. Darwin Fogt, Chief Executive Officer of eWellness Healthcare, owns Evolution Physical Therapy.

This past October, eWellness Healthcare announced the launch of its new patient lead generation platform, LeadRemedy.com. Lead Remedy increases a Practices’ social networks reach through tapping in to the employees of the practice and their social circles.

Each week, relevant physical therapy content is sent to practice employees to review and share. Upon a prospective patient viewing the content, the Practice’s brand is always present; the patient can book an evaluation appointment directly from the viewing page.

Mr. Darwin Fogt, eWellness Healthcare Chief Executive Officer, stated, “Physical Therapy Clinics are continually seeking to attract new patients in order to grow and maintain the success of their Practices. Traditionally, this is done through doctor referrals, word of mouth or advertising. Few practices use social media content to attract new patients. Typically, this lack of social media presence is due to the Practice Owners not having the capacity or capability to produce the content needed to be relevant to prospective patients. Practices that sign up for our Lead Remedy Service solve this outreach problem”.

eWellness Healthcare Corp. (EWLL), closed Friday's trading session at $0.125, down 1.96%, on 90,894 volume with 15 trades. The average volume for the last 60 days is 311,981 and the stock's 52-week low/high is $0.058/$0.1995.

GT Biopharma, Inc. (GTBP)

Stockopedia, Insider Financial, InvestorsHub, Stockhouse, and OTC Markets reported on GT Biopharma, Inc. (GTBP), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

GT Biopharma, Inc. focuses on innovative drugs for the treatment of cancer and CNS diseases (Neurology and Pain), along with other unmet medical needs. The Company’s lead oncology drug candidate is OXS-1550 (DT2219ARL). It owns the worldwide rights to commercialize OXS-1550. Its present CNS pipeline products include treatment for neuropathic pain, the symptoms of myasthenia gravis, as well as motion sickness.

A biotechnology company, GT Biopharma is based in Tampa, Florida. GT Biopharma completed its merger with GTP (Georgetown Translational Pharmaceuticals, Inc.). This merger brought in new management and a class of close-to-market Central Nervous System (CNS) products to GT Biopharma.

The Company is targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin’s lymphoma, and more. It is doing so with highly potent biopharmaceutical drugs designed for targeted therapy.

GT Biopharma’s OXS-1550 is an ADC (Antibody Drug Conjugate) drug. What makes OXS-1550 (DT2219ARL) different from other treatments, such as chemotherapy, is that the design of it is to specifically target and kill cancer cells while reducing damage to normal tissues.

OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

OXS-1550 targets cancer cells expressing the CD19 receptor or the CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of cytotoxic payload.

The Company’s OXS-3550 TriKE technology was developed by researchers at the University of Minnesota Masonic Cancer Center. This targeted immunotherapy directs immune cells to kill cancer cells while decreasing drug-related toxicity.

GT Biopharma’s CNS platform centers on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for CNS diseases. It also centers on guiding the products through the Food and Drug Administration (FDA) approval process to the NDA.

Earlier this month, GT Biopharma announced that it completed dosing in its Phase 1 clinical trial for GTP-004. This is the Company’s promising treatment for the symptoms of myasthenia gravis. Myasthenia gravis is a rare autoimmune muscle disease. It is caused by antibodies that attack certain components of muscles leading to varying degrees of weakness and fatigue.

The results provide evidence that GTP-004 enables the safe and well-tolerated administration of doses of pyridostigmine. The goal of the Phase 1 clinical trial is to demonstrate that GI side effects are safely reduced with GTP-004.

GTP-004 combines pyridostigmine with ondansetron, designed to soothe the gastro-intestinal (GI) side effects of pyridostigmine alone, providing the potential for a fully effective dose of pyridostigmine to be safely used. Based on the data, and discussions with key opinion leaders, GT Biopharma expects to be in a position to begin a Phase 2 clinical trial in patients in the second half of this year.

GT Biopharma, Inc. (GTBP), closed Friday's trading session at $4.20, down 1.18%, on 22,948 volume with 105 trades. The average volume for the last 60 days is 34,943 and the stock's 52-week low/high is $3.00/$40.50.

Moovly Media, Inc. (MVVYF)

OTC Markets, InvestorsHub, MarketWatch, Stockhouse, Stockwatch, and Barchart reported on Moovly Media, Inc. (MVVYF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Established in 2012, Moovly Media, Inc.’s vision is to become the number 1 platform for engaging, customizable multimedia content creation. Its mission is to enable everyone to create engaging multimedia content through making it affordable, intuitive, and also simple. The Company is the foremost provider of Cloud based tools to tell Marketing Communications and Training stories utilizing videos and presentations. OTCQB-listed, Moovly Media has its corporate office in Vancouver, British Columbia.

The Company’s advanced Studio editor has greater than 175M digital assets. It is seamlessly integrated by way of Moovly’s partnerships with Shutterstock and Videoblocks.

API and BOTs technology allows Moovly Media and third parties to automate some or all of the content-making process. This includes mass customization/personalization (Video version of MailMerge), automatic content creation, or updating through connecting data sources.

Moovly Media’s platform permits users to create animated videos and other multimedia content. This platform serves consumers, students, educational institutions, startups, SMEs (Small and Medium-sized Enterprises), brands, and blue chip multinational corporations. The Company offers Moovly for Business; Moovly for Small Businesses; Moovly for Large Enterprises; and Moovly for Agencies.

The Company also offers Moovly for Education. Students, teachers and school administrators can successfully create animated videos. Moovly offers special plans to teachers, students and employees with email addresses from educational (school or university) email domains. Users from educational email domains known by the Company automatically obtain a free Education plan.

Earlier this month, Moovly Media announced the second phase of integration into Shutterstock. The advanced integration will permit any Shutterstock customer, after linking their Shutterstock account to Moovly, to use any earlier purchased Shutterstock content in the Moovly Studio editor at no extra cost.

Additionally, Shutterstock customers can buy content through Moovly Studio using their existing Shutterstock credits. Shutterstock is a foremost international technology company. It offers a creative platform for high-quality assets, tools, as well as services.

Last week, Moovly Media announced that it was chosen as the preferred video content production partner by myBILLBOARD LLC. myBILLBOARD, on its website at myBILLBOARD.nyc, allows its customers to order on-demand, personalized, video segments. These are displayed in the heart of New York City's Times Square.

Moovly Media, Inc. (MVVYF), closed Friday's trading session at $0.0955, up 61.86%, on 125 volume with 1 trade. The average volume for the last 60 days is 9,265 and the stock's 52-week low/high is $0.059/$0.20.

Security Devices International, Inc. (SDEV)

OTC Markets, Stockhouse, YCharts, Zacks, MarketWatch, and InvestorsHub reported on Security Devices International, Inc. (SDEV), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

A technology company, Security Devices International, Inc. (SDI) specializes in the areas of Military, Law Enforcement, Corrections, and Private Security. The Company develops and manufactures innovative, less lethal equipment and munitions. SDI has its U.S. office in Wakefield, Massachusetts. In addition, it has a Canadian office in Burlington, Ontario.

SDI specializes in the development, manufacturing, and sale of next-generation 40mm less lethal ammunition. The design of its Family of Blunt Impact Projectiles (BIP) are for military, peacekeeping, homeland security, law enforcement, correctional services, and private sector security. They are ideal for crowd control scenarios. Moreover, they are adaptable to any 40mm caliber standard issue weapons and grenade launchers.

The development of SDI’s patented rounds has been for accuracy at longer ranges. This is to ensure the greater safety of the user. They provide an effective way of incapacitating subjects without causing lethal injury. This is due to the unique design of the BIP. The design utilizes an inventive collapsible head to mitigate kinetic energy. Therefore, this makes it highly effective even at a very close range.

SDI is shifting its emphasis to a Licensing model. It is working to sign agreements with strong partners around the world that have first-class manufacturing capabilities and large distribution networks.

The licensing of its intellectual property (IP) will be an important aspect of its strategy going forward. In addition, SDI has designed a Wireless Electric Projectile (WEP). It uses mini-harpoons to affix a bullet to a target’s clothing or body.

The Company has its SDI Instructor Training Course. This course provides professionally skilled instructors in less lethal for the military, law enforcement, correctional services, homeland security, and private sector security personnel. It is a one day less lethal training program. The program includes classroom instruction and live range firing.

Recently, Security Devices International announced the sale of 35,783,612 units on a private placement basis for gross proceeds of USD$3,793,063.

The Company’s Chief Executive Officer, Mr. Dean Thrasher, said, “Closing the financing gives the Company the capital to expand our intellectual property licensing efforts as well as launch our e-commerce store where the company plans to offer its products online to law enforcement and correctional services end-users.”

Security Devices International, Inc. (SDEV), closed Friday's trading session at $0.154, up 5.91%, on 500 volume with 1 trade. The average volume for the last 60 days is 22,242 and the stock's 52-week low/high is $0.061/$0.25.

Alacer Gold Corp. (ALIAF)

MarketWatch, TradingView, Investing, Silverstocker, InvestorPlace, GoldStockData, NorthernMiner, 4-Traders, Investopedia, OTC Markets, The Street, MiningFeeds, Information Vine, and Penny Stock Tweets reported on Alacer Gold Corp. (ALIAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Alacer Gold Corp. is a foremost intermediate gold mining company headquartered in Denver, Colorado. The Company has an 80 percent interest in the world-class Çöpler Gold Mine in Turkey operated by Anagold Madencilik Sanayi ve Ticaret A.S. The remaining 20 percent is owned by Lidya Madencilik Sanayi ve Ticaret A.S. Alacer Gold is pursuing initiatives to enhance value beyond the present mine plan. Alacer Gold’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s main emphasis is to take advantage of its cornerstone Çöpler Mine and strong balance sheet to maximize portfolio value, maximize free cash flow, and minimize project risk. The Çöpler Mine is located in east-central Turkey in the Erzincan Province.

The Çöpler Gold Mine produced 119,036 ounces of gold during 2016. Çöpler has considerable Probable Reserves of 4 million recoverable ounces and Measured and Indicated Resources of 6 million ounces of contained gold. These provide the basis for Çöpler’s 20 year mine life.

At present, the Mine is an open-pit, heap-leach operation producing low-cost gold from oxide ore. Over the life of the present heap-leach project, roughly 76 percent of the gold contained in the oxide ore is expected to be recovered.

In May of 2016, Alacer Gold’s Board of Directors approved full construction of the Sulfide Project at the Çöpler Gold Mine, with first gold pour expected in Q3 of 2018. The Çöpler orebody contains refractory sulfide ore. This necessitates a different processing solution than heap-leaching to extract the gold.

The Sulfide Project construction is over 75 percent complete, under budget, and on course for first gold production in Q3 2018. The expectation is that the Sulfide Project will deliver long-term growth with strong financial returns and adds 20 years of production at the Çöpler Gold Mine. The Sulfide Project will bring Çöpler’s remaining life-of-mine gold production to greater than 2 million ounces at All-in Sustaining Costs averaging $645 per ounce.

This week, Alacer Gold announced full-year 2017 production results, unaudited full-year cost results, and 2018 production and cost guidance.

Mr. Rod Antal, President and Chief Executive Officer of Alacer Gold, stated, “I am pleased to report that we produced 168,1631 ounces of gold at unaudited All-in Sustaining Costs (AISC) of $685 per ounce in 2017, meeting our original production and beating AISC cost guidance for the year. The production initiatives generated through our operational excellence program were very successful, delivering 64,542 ounces in the fourth quarter, making it the strongest quarter of the year… 2018 production guidance is 120,000 to 190,000 ounces from Çöpler oxides and sulfides. We also expect initial mining at a new oxide deposit, Çakmaktepe, later this year.”

Alacer Gold Corp. (ALIAF), closed Friday's trading session at $1.81, down 1.63%, on 7,591 volume with 16 trades. The average volume for the last 60 days is 19,580 and the stock's 52-week low/high is $1.42/$2.37.

CareView Communications, Inc. (CRVW)

Tiny Gems, BabyBulls, Stock Stars, MonsterStocksPick, FeedBlitz, Real Pennies, PennyTrader Publisher, Wall Street Resources, and MissionIR reported previously on CareView Communications, Inc. (CRVW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CareView Communications, Inc. is an information technology (IT) provider to the healthcare industry. It provides the next generation of patient care via its leading-edge data and patient monitoring system. The system connects patients, families, and healthcare professionals (the CareView System®). The CareView System can help a hospital reduce sitter costs, patient falls and injuries, manage patient flow, improve internal communications, and consolidate vendors. CareView Communications is based in Lewisville, Texas.

CareView’s goal is to be the leading provider of products and on-demand application services for the healthcare industry. This is through specializing in bedside video monitoring, archiving and patient care documentation systems and patient entertainment services. The Company’s proprietary, high-speed data network system may be installed throughout a healthcare facility to provide the facility with recurring revenue and infrastructure for future applications.

The CareView System allows for close observation of high-risk patients from manifold locations. This is to lessen sitter costs and manage staffing resources more efficiently. In addition, the CareView Connect® mobile application provides patient monitoring and critical communication tools from an existing Wi-Fi Android or iOS device.

The CareView System is HIPAA-compliant (Health Insurance Portability and Accountability Act) and secure. The System does not record anything. Moreover, it can include consent processes and privacy options.

Regarding hospital benefits, the CareView System enables patients to watch first-run movies and access high-speed internet. The result of this is increased patient satisfaction.

The CareView System employs an infrared camera in patient rooms to deliver real-time visual monitoring around the clock. The Company installs its equipment in healthcare facilities at no charge. It then produces revenue from subscriptions to its set of products and services. These are priced as a bundled service.

In 2017, CareView Communications executed an agreement with Dish Network, LLC, to become a Private Cable Operator (PCO). This agreement enables the Company to provide television network services via Dish Network as part of its full suite of products and services offered by way of its CareView System®.

The CareView system is installed in thousands of beds in greater than 100 hospitals around the U.S. The Company’s cost effective platform and setup capitalizes on fixed cameras in the room. The system is username and password protected. It is accessible to qualified users on site only.

CareView Communications, Inc. (CRVW), closed Friday's trading session at $0.034, down 12.37%, on 19,813 volume with 3 trades. The average volume for the last 60 days is 105,047 and the stock's 52-week low/high is $0.021/$0.215.

graphic

The QualityStocks
Company Corner

graphic
graphic

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.61, up 0.63%, on 340,747 volume with 388 trades. The stock’s average daily volume over the past 60 days is 517,257 and its 52-week low/high is $0.27/$2.54.

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) demonstrated several transformative developments in 2017. The company’s Intellectual Property (“IP”) was strengthened, it was awarded broad patents, and it secured finances during the year. Now, Lexaria is concentrating on making 2018 an even more fruitful year.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Eyes Bright Future Following 2017 Success

NetworkNewsWire Announces Publication on Companies Addressing the Hazards of Smoking via New Delivery Methods

Intriguing Research into Pathways to Limit Nicotine, Quit Cigarette Use

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.69, off by 2.82%, on 148,621 volume with 120 trades. The stock’s average daily volume over the past 60 days is 243,538 and its 52-week low/high is $0.40/$2.75.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB:CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products. To view the full publication, titled “Repeal of Cole Memo Raises Concerns, Opportunities for Cannabis Industry,” visit: https://www.networknewswire.com/repeal-cole-memo-raises-concerns-opportunities-cannabis-industry/

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

NetworkNewsWire Announces Publication on Opportunities Amid Cannabis Crackdown

Repeal of Cole Memo Raises Concerns, Opportunities for Cannabis Industry

NetworkNewsWire Announces Publication on Transformative Technology at Play in Cryptocurrency Markets

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $1.39, up 13.01%, on 689,568 volume with 440 trades. The stock’s average daily volume over the past 60 days is 208,334 and its 52-week low/high is $0.50/$2.119.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Announces 2.07 % Li2O and 213.96 ppm Ta Over 18.0 m at Case Lake

MGX Minerals Partners with Highbury Energy to Extract Nickel, Vanadium, and Cobalt from Petroleum Coke

MGX Minerals Appoints Christopher Wolfenberg to Board of Directors

Tapinator, Inc. (TAPM)

The QualityStocks Daily Newsletter would like to spotlight Tapinator, Inc. (TAPM). Today, Tapinator, Inc. closed trading at $0.40, up 10.62%, on 174,140 volume with 66 trades. The stock’s average daily volume over the past 60 days is 255,200 and its 52-week low/high is $0.0711/$0.72.

Tapinator, Inc. (TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company's portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator's business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as "New Games We Love." During the game's first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator's strong creative team of developers, strategists and product specialists. The company's Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator's diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game's currency. Tapinator's portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator's gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019. Disclaimer

Tapinator, Inc. Blog

Tapinator, Inc. News:

Blockchain Emerging as a New Frontier for the Gaming Industry

Tapinator Introduces New Subsidiary Focused on Decentralized Blockchain Apps

NetworkNewsWire Announces Publication on M&A in the Mobile Gaming Industry

Medical Innovation Holdings, Inc. (MIHI)

The QualityStocks Daily Newsletter would like to spotlight Medical Innovation Holdings, Inc. (MIHI). Today, Medical Innovation Holdings, Inc. closed trading at $0.265, up 10.42%, on 72,877 volume with 22 trades. The stock’s average daily volume over the past 60 days is 56,806, and its 52-week low/high is $0.1265/$3.99.

Medical Innovation Holdings, Inc. (MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company's MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company's telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not accept insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient's primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package. Disclaimer

Medical Innovation Holdings, Inc. Company Blog

Medical Innovation Holdings, Inc. News:

MIHI Launches a New Health Care Sharing Organization (HCSO) Designed for 58 Million US-based Hispanics Requiring Coverage

Medical Innovation Holdings, Inc. (OTC: MIHI) Announces a Strategic Arrangement With AeonMD, LLC, a Leading Provider of Wellness Therapies for Physician Offices

Medical Innovation Holdings to be Featured on National Radio Telecasted Tuesday October 24th, 2017 at 10AM ET on Beasley Broadcasting

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $1.26, up 5.00%, on 137,029 volume with 100 trades. The stock’s average daily volume over the past 60 days is 124,346 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub Raises $3.8 Million Through Successful Warrant Exercise

ORHub, Inc. Sponsors DOCSF18: Digital Orthopedics Conference Hosted by UCSF

ORHub, Inc. (ORHB) Provides 2017 Business Highlights and Sets Special Warrant Exercise Price

Petrogress, Inc. (PGAS)

The QualityStocks Daily Newsletter would like to spotlight Petrogress, Inc. (PGAS). Today, Petrogress, Inc. closed trading at $0.0305, up 1.67%, on 24,652 volume with 4 trades. The stock’s average daily volume over the past 60 days is 396,868, and its 52-week low/high is $0.0161/$0.072.

Petrogress, Inc. (PGAS) founded in 2009, owns and operates a fleet of tankers from its base in the historic Port of Piraeus, Greece, through a series of Marshall Islands subsidiaries. The company is an international merchant of petroleum products which includes reliably marketing and trading crude oil, distillates, and refined products off the coast of West Africa. The company also operates service and shipping facilities at the Port of Limassol in Cyprus and the Port of Tema, Greater Accra, in Ghana. It is actively seeking expansion opportunities, including in operating and developing natural gas production and transmission facilities along with LNG processing in the U.S., refinery operations in north and west Africa, and the transport and sales of LNG in Europe.

Petrogress has created a diversified revenue stream, giving it a significant advantage over similar companies working in the oil and gas shipping arena. A case in point is the recent formation of "PG Cypyard & Offshore Service Terminal Ltd. ("Cypyard"), through the company's wholly owned subsidiary, Petrogress Int'l, LLC. Cypyard is concluding negotiations for an operations and management agreement covering ports in Hellenic Cyprus, including the Port of Limassol, directly with the Cyprus Ports Authority. Current plans include a long-term lease with renewal options covering all in-place port facilities, including floating dock and dry dock areas, with cranes and scaffolding, construction and repair workshops and storage, and complete on-site administrative and office space.

"I think the opportunities there are great, and dealing directly with partners in government has numerous benefits," said Christos P. Traios, president of Petrogress Inc. in a news release announcing the venture. The recent appointment of two industry experts to the Petrogress Advisory Board is expected to help the company capitalize on future growth opportunities while simultaneously developing a comprehensive U.S. and international lobbying and government outreach program to facilitate business plans in the U.S., European Union and Africa.

Additional Petrogress Inc. subsidiaries are:

  • Petrogress Co. Ltd., an international merchant of petroleum products that combines regional market knowledge with over 20 years of excellent shipping experience.
  • Petrogress Co. Ltd., an international merchant of petroleum products that combines regional market knowledge with over 20 years of excellent shipping experience.
  • Petrogress Oil & Gas Energy Inc., which has expansion plans through a supply of liquified natural gas located in the oil fields of Texas with an eye toward exporting LNG to Mediterranean markets.

Petrogress continues to "adjust its sails" in order to meet new challenges. Opportunities include upstream oil resources and exploration, the addition of more product fleet carriers, downstream movement of petroleum products from refineries to finished sales, and sea transportation of liquified natural gas. A closely followed economist, Jim O'Neill, states that oil prices could spike more than 25% in the next year. O'Neill, now an economics professor at the University of Manchester, says the market is finally waking up to the fact that global economic growth is gaining momentum and likely expanding at 4 percent or higher. That means there will be more demand for oil, the article states, which translates into brighter days ahead for companies like Petrogress. Disclaimer

Petrogress, Inc. Company Blog

Petrogress, Inc. News:

Petrogress, Inc. Announces Joint Venture with International Marine Fleet & Offshore Support Provider

NetworkNewsWire Releases Exclusive Audio Interview with Petrogress Inc. (PGAS)

Petrogress, Inc. (PGAS) is “One to Watch”

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

MarketClub Analysis
(FORD) +137.90%

2.

QualityStocks
(MVVYF) +61.86%

3.

Trader Power News
(NCNA) +41.55%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251